Abstract:AIM:To examine the effect of celecoxib on tumor growth and angiogenesis in an orthotopic implantation tumor model of colon cancer.METHODS:Human colorectal adenocarcinoma HT-29 cells were implanted subcutaneously in nude mice. Four groups of animals received different doses of celecoxib after tumor implantation. After 42 days, all animals were evaluated for changes in body weight, the volume and weight of colorectal tumors, and tumor growth inhibition. The content of prostaglandin E(2) (PGE(2)) in the tumor tissue homogenate was estimated by radioimmunoassay (RIA). Cyclooxygenase-2 (COX-2) and CD34 expression in tumor tissue was assessed by immunohistochemistry, and the microvessel density (MVD) of tumor tissue was determined. Apoptosis of the tumor cells was detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). The expression of vascular endothelial growth factor (VEGF) mRNA and matrix metalloproteinase-2 (MMP-2) mRNA extracted from the tumor tissue was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR).RESULTS:There was no statistically significant change in the animals' body weight between the treatment groups. However, with increasing doses of celecoxib, the volume and weight of the tumor decreased. The rates of tumor growth inhibition for the L (low), M (medium) and H (high) groups were 25.30%, 38.80%, and 76.92%, respectively, which were significant compared to the C (control) group. There were significant differences in COX-2 expression in the tumor tissue between all groups, except between the L and M groups. Celecoxib exposure also reduced PGE2 levels in the tumor tissue homogenates. The level of PGE(2) correlated to the weight of tumor (r=0.8814, P < 0.05) and to COX-2 expression (r=0.8249, Puse < 0.05). Compared to the control group, the tumor cells from celecoxib-treated mice had a significantly higher apoptotic index. Celecoxib also decreased CD34(+) expression in tumors from treated mice. There were significant differences in the MVD between all groups except between groups H and M. Celecoxib significantly reduced the expression of VEGF and MMP-2 mRNA in the group H but not in L and M groups. The MVD in tumor tissue was closely related to the PGE2 levels, as well as the expression of VEGF and MMP-2 mRNA (r = 0.9006, r = 0.8573 and r = 0.6427, respectively; P < 0.05).CONCLUSIONS:By inhibiting COX-2, PGE(2) synthesis, and VEGF and MMP-2 mRNA expression in tumor tissue, celecoxib enhances tumor cell apoptosis, thereby inhibiting the growth and angiogenesis of orthotopically implanted tumors in a mouse model of human colorectal cancer.

Study on Enhancement of Radiosensitivity in Colon Cancer Carcinoma Cell Line HT-29 by Celecoxib in Vitro and in Vivo

[Effect of Selective Cyclooxygenase-2 Inhibitor Celebrex on Expression of Vascular Endothelial Growth Factor (VEGF) in Pancreatic Carcinoma].

Impact of the Selective Cyclooxygenase-2 Inhibitor Celebrex on Angiogenesis in Pancreatic Carcinoma

Radiosensitization of Celecoxib on Human Lung Adenocarcinoma Cell Line A549 and Inhibition of Migration Ability in Vitro

Radiosensitizing Effect of Celecoxib on Human Pancreatic Carcinoma

Study of the mechanism of radiation sensitizing effect of celecoxib on breast cancer cells with different estrogen receptors status

Celecoxib's Radiosensitizing Effects on Three Different Human Cancer Cell Lines

Radiosensitizing Effects of COX-2 Inhibitor Celecoxib on the Five Different Human Malignent Cell Lines

Effect of Celecoxib on Growth and Angiogenesis of Orthotopic Transplantation Tumor of Experimental Colorectal Cancer

Radiosensitizing effects of cyclooxygenase-2 selective inhibitor LM-1685 on A549 human lung adenocarcinoma cells

Modulating Effect of Celecoxib to Suppress Proliferation and the Molecular Mechanism in Caco-2 of Colon Carcinoma Cell Line

Effect of celecoxib on expressions of MIF, PTEN and Caspase-3 in human colon cancer cell line HT-29

Experimental Study on Selective Cyclooxygenase-2 Inhibitor Combined with Radiotherapy for Human Prostate Carcinoma Xenografts in Nude Mice

Celecoxib Alleviates Radiation-Induced Brain Injury in Rats by Maintaining the Integrity of Blood-Brain Barrier

The Effect of a Selective COX-2 Inhibitor on Cell Growth in Human Colorectal Cancer Cell Line

Celecoxib Inhibits Tumor Growth and Angiogenesis in an Orthotopic Implantation Tumor Model of Human Colon Cancer.

Increase of Cyclooxygenase-2 Inhibition with Celecoxib Combined with 5-FU Enhances Tumor Cell Apoptosis and Antitumor Efficacy in a Subcutaneous Implantation Tumor Model of Human Colon Cancer

Antitumor Activity of the Selective Cyclooxygenase-2 Inhibitor, Celecoxib, on Breast Cancer in Vitro and in Vivo

Celecoxib Radiosensitizes the Human Cervical Cancer HeLa Cell Line Via a Mechanism Dependent on Reduced Cyclo-Oxygenase-2 and Vascular Endothelial Growth Factor C Expression

Radiosensitization of Celecoxib for Glioma Cells

Study on the Mechanism of Celecoxib on Synergetic Anti- Tumor Role in Gastric Cancer in Vitro